Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease

Background: Clostridium difficile is an important cause of diarrhoea in hospitalised patients. An increasing number of cases of C difficile colitis occur in patients with inflammatory bowel disease (IBD)—Crohn’s disease (CD), ulcerative colitis (UC). Objective: To estimate the potential excess morbidity and mortality associated with C difficile in hospitalised patients with IBD. Methods: Data from the Nationwide Inpatient Sample (2003) were analysed and outcomes were examined of patients hospitalised with both C difficile colitis and IBD compared with those hospitalised for either condition alone. The primary outcome was in-hospital mortality. A subgroup analysis was also performed comparing outcomes of C difficile infection in patients with CD and UC. Results: 2804 discharges were diagnosed as having both C difficile and IBD, 44 400 as having C difficile alone, and 77 366 as having IBD alone. On multivariate analysis, patients in the C difficile–IBD group had a four times greater mortality than patients admitted to hospital for IBD alone (aOR = 4.7, 95% CI 2.9 to 7.9) or C difficile alone (aOR = 2.2, 95% CI 1.4 to 3.4), and stayed in the hospital for three days longer (95% CI 2.3 to 3.7 days). Significantly higher mortality, endoscopy and surgery rates were found in patients with UC compared with CD (p<0.05), but no significant difference in length of stay or median hospital charge between the two groups was seen. Conclusions: C difficile colitis is associated with a significant healthcare burden in hospitalised patients with IBD and carries a higher mortality than in patients with C difficile without underlying IBD.

[1]  Kimberly A. Reske,et al.  Incidence of Clostridium difficile infection in inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  D. Binion,et al.  Clostridium difficile Enteritis: An Early Postoperative Complication in Inflammatory Bowel Disease Patients After Colectomy , 2007, Journal of Gastrointestinal Surgery.

[3]  J. Heins Clostridium difficile-associated disease. , 2006, South Dakota medicine : the journal of the South Dakota State Medical Association.

[4]  Victoria J. Fraser,et al.  ICD-9 Codes and Surveillance for Clostridium difficile–associated Disease , 2006, Emerging infectious diseases.

[5]  D. Morgan,et al.  The Burden of Gastrointestinal and Liver Diseases, 2006 , 2006, The American Journal of Gastroenterology.

[6]  M. Owings,et al.  Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. , 2006, Emerging infectious diseases.

[7]  A. Barkun,et al.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. , 2005, JAMA.

[8]  J. Leighton,et al.  The Diagnostic Yield of Stool Pathogen Studies During Relapses of Inflammatory Bowel Disease , 2004, Journal of clinical gastroenterology.

[9]  Louis Valiquette,et al.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity , 2004, Canadian Medical Association Journal.

[10]  D. Rampton,et al.  Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool , 2004, European journal of gastroenterology & hepatology.

[11]  A. Huang,et al.  Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies , 2004, Canadian Medical Association Journal.

[12]  C. Kelly,et al.  Underlying Disease Severity as a Major Risk Factor for Nosocomial Clostridium difficile Diarrhea , 2002, Infection Control &#x0026; Hospital Epidemiology.

[13]  A. Morris,et al.  Clostridium difficile colitis: an increasingly aggressive iatrogenic disease? , 2002, Archives of surgery.

[14]  C. Kelly,et al.  Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  A. Sonnenberg,et al.  Medical diagnoses and procedures associated with Clostridium difficile colitis , 2000, American Journal of Gastroenterology.

[16]  L. Uscanga,et al.  Toxic pseudomembranous colitis in a patient with ulcerative colitis. , 2000, Inflammatory bowel diseases.

[17]  S. Meyers Clostridium difficile Colitis , 1999, American Journal of Gastroenterology.

[18]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[19]  M. Scheurlen,et al.  Microbic Superinfection in Relapse of Inflammatory Bowel Disease , 1992, Journal of clinical gastroenterology.

[20]  J. Gryboski Clostridium difficile in Inflammatory Bowel Disease Relapse , 1991, Journal of pediatric gastroenterology and nutrition.

[21]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[22]  R. Möllby,et al.  Occurrence of Clostridium difficile toxin in inflammatory bowel disease. , 1983, Scandinavian journal of gastroenterology.

[23]  J. Bartlett,et al.  Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. , 1978, The New England journal of medicine.